Amgen Seeks Dismissal of Patent Extension Lawsuit Over Arthritis Drug Enbrel

In a recent legal development, Amgen has requested a Virginia federal judge to dismiss a proposed class action lawsuit that accuses the company of improperly extending and fortifying its patent rights to obstruct more affordable alternatives to its widely-used arthritis medication, Enbrel. The pharmaceutical giant insists that Enbrel is shielded by valid patents and judicial determinations affirming their legitimacy. For more in-depth coverage on this legal case, visit Law360.